Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00669890 · ClinicalTrials.gov registry record · Phase 1
Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML
A Phase 1 study, sponsored by New York Medical College.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00669890 is a Phase 1 study that was terminated before completion, run by New York Medical College. The registered enrollment target is 12 participants.
The verdict
NCT00669890, a Phase 1 study, was terminated before completion, sponsored by New York Medical College.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The addition of gemtuzumab ozogamicin (GO) in combination with Busulfan/Cyclophosphamide followed by AlloSCT in patients with high risk CD33+ AML/JMML/MDS will be safe and well tolerated. This study will attempt to determine the maximum tolerated dose of the immune therapy (gemtuzumab) when given in combination with the myeloablative (high dose) drugs used in this study for allogeneic stem cell transplant. (Part A)
Interventions
- DRUG Cyclophosphamide
- DRUG Busulfan
- DRUG Gemtuzumab Ozogamicin
- DRUG Thymoglobulin
- DRUG Tacrolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2004-05 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00669890
The ClinicalTrials.gov registry entry for NCT00669890 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York Medical College, which has 47 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00669890 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00669890 about?
NCT00669890 is a clinical study titled "Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML". The addition of gemtuzumab ozogamicin (GO) in combination with Busulfan/Cyclophosphamide followed by AlloSCT in patients with high risk CD33+ AML/JMML/MDS will be safe and well tolerated. This study will attempt to determine the maximum tolerated dose of the immune therapy (gemtuzumab) when given i...
What is the current status of trial NCT00669890?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2004-05. Estimated completion is 2013-12.
What interventions are being tested in trial NCT00669890?
The interventions under investigation include: Cyclophosphamide (DRUG), Busulfan (DRUG), Gemtuzumab Ozogamicin (DRUG), Thymoglobulin (DRUG), Tacrolimus (DRUG).
Who is sponsoring clinical trial NCT00669890?
This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.